在炎症性肠道疾病中发现生物活性微生物基因产物
Yancong Zhang1,2,3, Amrisha Bhosle1,2,3, Sena Bae2,3,4
1Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nature
|May 25, 2022
概括
研究人员确定了超过34万个可能与炎症性肠道疾病 (IBD) 相关的微生物蛋白家族. 这一发现扩大了对微生物组的理解
科学领域:
- 微生物组研究
- 免疫学
- 生物信息学
背景情况:
- 在炎症性肠道疾病 (IBD) 中,微生物群落及其生物活性化合物受到干扰.
- 很大一部分微生物蛋白质,特别是在肠道中,仍然没有特征,但可能具有生物活性.
研究的目的:
- 系统地确定与IBD肠道炎症相关的潜在生物活性微生物蛋白家族.
- 在功能上描述之前未注释的IBD相关的微生物蛋白质.
主要方法:
- 使用元基因组学,元转录组学和元蛋白组学的组合来识别和优先考虑生物活性微生物蛋白.
- 开发并使用MetaWIBELE工作流程来识别微生物组中的新生物活性元素.
- 通过有针对性的实验验证实预测,包括评估免疫性和生物膜形成.
主要成果:
- 在IBD的背景下确定了超过34万个潜在的生物活性蛋白家族,其中大约一半以前没有被描述.
- 提供了参与宿主微生物相互作用的特定蛋白质的生物活性证据,例如粘附因子和·维尔布兰德样因子.
- 证明了Enterobacteriaceae菌株的差异性免疫性,并确定了von Willebrand因子对象在Bacteroides生物膜形成中的作用.
结论:
- 在多种社区和表型中发现新生物活性元素的MetaWIBELE方法是一种可通用的方法.
- 成千上万的候选微生物蛋白可能与IBD的宿主免疫系统相互作用,提供潜在的治疗点.
- 这项工作扩大了对慢性病中的生物活性基因产品的理解,并为治疗开发提供了一个摘要.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
2.7K
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
1.9K
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
434
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
434
01:29Inflammatory Bowel Disease IV: Pharmacological Management
206
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
206
01:30Inflammatory Bowel Disease II: Crohn's Disease
409
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
409
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
351
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
351
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
01:29Microorganisms in Medicine and Therapeutics
389
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
389